Literature DB >> 13678758

Prevalence of thyroid cancer in Graves' disease: a retrospective study of a cohort of 103 patients treated surgically.

J Gerenova1, M Buysschaert, C Y. de Burbure, Ch Daumerie.   

Abstract

BACKGROUND: Thyroid nodules in patients with Graves' disease (GD) are common, and the incidence of coexisting thyroid carcinoma is a much debated subject, which is addressed in this study.
METHODS: In order to determine the incidence rate of coexisting malignancy, a retrospective study was conducted on 103 patients who underwent surgery for GD between 1990 and 2000 at the Cliniques Universitaires Saint-Luc in Brussels, Belgium. The patients were classified into groups. Those in group I had a solitary palpable nodule (4.9%), those in group II multiple palpable nodules (12.6%), group IIIa had nodule(s) revealed by imaging techniques (incidentalomas: 17.5%), and group IIIb had diffuse non-nodular goiter (65%).
RESULTS: Patients with nodules (groups I, II, and IIIa) were found to have significantly more thyroid carcinomas than those with diffuse non-nodular goiters (P=0.02), and the rate of malignancy was significantly increased when the nodules were palpable (groups I and II; P=0.03). Eight patients (7.8%) were diagnosed as having coexisting carcinomas, all but one being microcarcinomas.
CONCLUSIONS: Well-differentiated papillary carcinomas are found to coexist with GD surgically treated (7.8%) and occur most frequently in GD with palpable nodular lesions (35%). Even though the majority (88%) of coexisting carcinomas are microcarcinomas, the presence of palpable nodules justifies further evaluation and follow-up.

Entities:  

Year:  2003        PMID: 13678758     DOI: 10.1016/s0953-6205(03)00105-5

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  11 in total

1.  Risk factors of thyroid cancer in Babol, Northern Iran.

Authors:  Zoleika Moazezi; Mahmoud Mahmoudi; Yousef Yahyahpour; Alireza Alaleh
Journal:  Caspian J Intern Med       Date:  2011

2.  Marine-Lenhart syndrome.

Authors:  Mehtap Cakir
Journal:  J Natl Med Assoc       Date:  2005-07       Impact factor: 1.798

3.  Thyroid carcinoma in patients with Graves' disease: an institutional experience.

Authors:  Shuanzeng Wei; Zubair W Baloch; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

4.  Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?

Authors:  C Daumerie; A Boschi; P Perros
Journal:  Eur Thyroid J       Date:  2012-06-07

5.  Predictive factors of thyroid cancer in patients with Graves' disease.

Authors:  Meng Ren; Mu Chao Wu; Chang Zhen Shang; Xiao Yi Wang; Jing Lu Zhang; Hua Cheng; Ming Tong Xu; Li Yan
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

Review 6.  TSH receptor autoantibodies.

Authors:  Krzysztof Michalek; Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Autoimmun Rev       Date:  2009-03-27       Impact factor: 9.754

7.  Can we still consider thyroid hyperfunction a protective condition for the onset of thyroid cancer?

Authors:  Elena Bonati; Stefania Bettoni; Tommaso Loderer; Paolo Del Rio
Journal:  Gland Surg       Date:  2021-04

8.  Clinicopathologic features and treatment outcomes in differentiated thyroid carcinoma patients with concurrent Graves' disease.

Authors:  Jandee Lee; Kee Hyun Nam; Woung Youn Chung; Euy-Young Soh; Cheong Soo Park
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

9.  Pertechnetate thyroid scan in Marine-Lenhart syndrome.

Authors:  Jayanthi Roop Mohan; Sampath Santhosh; Ashwani Sood; Anish Bhattacharya; Bhagwant Rai Mittall
Journal:  Indian J Nucl Med       Date:  2013-04

10.  Frequency of thyroid nodules and thyroid cancer in thyroidectomized patients with Graves' disease.

Authors:  Caglar Keskin; Mustafa Sahin; Rovshan Hasanov; Berna Imge Aydogan; Ozgur Demir; Rıfat Emral; Sevim Gullu; Murat Faik Erdogan; Vedia Gedik; Ali Riza Uysal; Nilgun Baskal; Demet Corapcioglu
Journal:  Arch Med Sci       Date:  2019-01-11       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.